is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

Partners

To serve our physician clinician clients, Inform Diagnostics has carefully selected and partnered with a number of specialized vendors.

We work closely with each partner to offer solutions that maximize the efficiency of your practice.

  • gMed — We offer gMedConnect to gastroenterology practices for a low monthly subscription fee.
  • ProVation — Through Inform Diagnostics partnership with ProVation, you can add the ProVation MD endoscopy report writing software to your practice at an affordable price.
  • Modernizing Medicine — For dermatologists who use the EMA EMR, we have significantly enhanced how our pathologists use diagnostic information.

The Inform Diagnostics team proudly brings these outstanding technology companies to our physician clients to enhance the day-to-day business of running your practice.

Inform Diagnostics is investing in where the market is going: converged, cloud-ready, fully-integrated technology solutions. We expand the diversity of our offerings and our ability to deliver relevant practice solutions through our strategic relationships with leading specialty-specific vendors. Find the program that fits your business.

Continuous electronic connection with patients and healthcare partners is the business model of the new millennium. Downtime is not an option. That's why Inform Diagnostics is offering practice solutions designed specifically for this new electronic economy. Inform Diagnostics is aggressively building unique specialty-specific expertise with every technology partnership and e-business solution that we offer in order to provide customized architectures and products that fit your practice.

Importantly, our consulting expertise and implementation experience deepens and broadens our solution portfolio and industry capabilities. Our broad spectrum of best-in-class service offerings aims to meet your every business need, whether simple or complex.

Contact Inform Diagnostics to learn how we can assist your practice
Call 1.866.588.3280 or visit our Contact Page
.

Choose Inform Diagnostics for Your Patients


Learn more about Inform Diagnostics' pathology services

Learn More »

We have been using Miraca for about 20 months, and they are outstanding. They have a daily conference with all of their Dermpaths across the country where they [collaborate on] tough cases.
— Joel Cohen, MD


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading


November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading


September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading